SecBot SecBot
SECBOTREPLAY Home › Report › PCVX

PCVX · Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2…

Vaxcyte, Inc. · PRESS-RELEASE filed Mar 23, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 23, 2026 at 08:30 ET

Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pneumococcal vaccine VAX-31. Topline data from OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in H1 2027. The trials are designed to support a future Biologics License Application (BLA) submission to the FDA, building on prior Breakthrough Therapy designation for VAX-31 in preventing invasive pneumococcal disease and pneumonia.

  • Enrollment completed in OPUS-1 (n≈4,000) and OPUS-2 (n≈1,300) Phase 3 trials for VAX-31.
  • Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.
  • OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Capvaxive® (PCV21) and Prevnar 20® (PCV20) in adults ≥50 years.
  • VAX-31 has FDA Breakthrough Therapy Designation for prevention of both IPD and pneumococcal pneumonia in adults.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access